Allakos Inc. (ALLK): Price and Financial Metrics


Allakos Inc. (ALLK): $2.81

0.15 (+5.64%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ALLK to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ALLK Stock Price Chart Interactive Chart >

Price chart for ALLK

ALLK Price/Volume Stats

Current price $2.81 52-week high $11.73
Prev. close $2.66 52-week low $2.56
Day low $2.56 Volume 776,800
Day high $2.81 Avg. volume 1,511,576
50-day MA $4.44 Dividend yield N/A
200-day MA $7.39 Market Cap 153.92M

Allakos Inc. (ALLK) Company Bio


Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. The company was founded in 2012 and is based in San Carlos, California.


ALLK Latest News Stream


Event/Time News Detail
Loading, please wait...

ALLK Latest Social Stream


Loading social stream, please wait...

View Full ALLK Social Stream

Latest ALLK News From Around the Web

Below are the latest news stories about Allakos Inc that investors may wish to consider to help them evaluate ALLK as an investment opportunity.

Allakos (ALLK) to Report Q4 Earnings: What's in the Cards?

On Allakos' (ALLK) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's lead pipeline candidate, lirentelimab.

Yahoo | February 21, 2022

Top 10 Stock Picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital

In this article, we discuss the top 10 stock picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. You can skip our detailed analysis of Akkaraju and Dybbs’ history, investment philosophy, and hedge fund performance, and go directly to the Top 5 Stock Picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. Dr. Srinivas Akkaraju […]

Yahoo | February 17, 2022

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amarin (AMRN), Crispr Therapeutics AG (CRSP) and Allakos (ALLK)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amarin (AMRN – Research Report), Crispr Therapeutics AG (CRSP – Research Report) and Allakos (ALLK – Research Report). Amarin (AMRN) Leerink Partners analyst Roanna Ruiz maintained a Buy rating on Amarin today and set a price target of $10.00. The company's shares closed last Tuesday at $3.58, close to its 52-week low of $2.79. According to TipRanks.com, Ruiz is ranked 0 out of 5 stars with an average return of -20.3% and a 21.6% success rate. Smith covers the Healthcare sector, focusing on stocks such as Connect Biopharma Holdings, Madrigal Pharmaceuticals, and Prometheus Biosciences.

Brian Anderson on TipRanks | February 16, 2022

Handelsbanken Fonder AB Buys FREYR Battery, Pfizer Inc, GXO Logistics Inc, Sells SVB Financial ...

Investment company Handelsbanken Fonder AB (Current Portfolio) buys FREYR Battery, Pfizer Inc, GXO Logistics Inc, Alnylam Pharmaceuticals Inc, Fair Isaac Corp, sells SVB Financial Group, Ameresco Inc, Activision Blizzard Inc, Wolfspeed Inc, Teladoc Health Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Handelsbanken Fonder AB.

Yahoo | February 8, 2022

Silvant Capital Management LLC Buys Netflix Inc, Pfizer Inc, Natera Inc, Sells Visa Inc, ...

Investment company Silvant Capital Management LLC (Current Portfolio) buys Netflix Inc, Pfizer Inc, Natera Inc, Union Pacific Corp, SentinelOne Inc, sells Visa Inc, Mastercard Inc, Comcast Corp, UnitedHealth Group Inc, Cardlytics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Silvant Capital Management LLC.

Yahoo | February 7, 2022

Read More 'ALLK' Stories Here

ALLK Price Returns

1-mo -25.46%
3-mo -49.73%
6-mo -64.14%
1-year -72.30%
3-year -29.29%
5-year N/A
YTD -71.30%
2021 -30.07%
2020 46.81%
2019 82.44%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7016 seconds.